Meeting
2024 ASCO Annual Meeting
Nutraceutical and dietary supplement use in the cancer population: The impact of evidence-based education.
Authors
Rubal Sharma
Staten Island University Hospital, Staten Island, NY
Rubal Sharma , Laura Longo , Maureen Gonzalez , Samantha Paone , Louise Madrigal , Jon Javor , Yue Faat Raymond Kwok , Alexander Bershadskiy , Meekoo Dhar , Mario R Castellanos
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Prevention, Risk Reduction, and Genetics
Track
Prevention, Risk Reduction, and Genetics
Sub Track
Health Promotion/Behaviors
Citation
J Clin Oncol 42, 2024 (suppl 16; abstr 10611)
DOI
10.1200/JCO.2024.42.16_suppl.10611
Abstract #
10611
Poster Bd #
138
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
The safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer.
First Author: Jieer Ying
Poster
2024 ASCO Annual Meeting
A phase Ib/IIa trial to evaluate the safety and efficacy of PM8002, a bispecific antibody targeting PD-L1 and VEGF-A, as a monotherapy in patients with advanced NSCLC.
First Author: Chunjiao Wu
Poster
2024 ASCO Annual Meeting
Final analysis of the randomized phase 3 ESCORT-1st trial: Camrelizumab plus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma.
First Author: Huiyan Luo
Poster
2024 ASCO Annual Meeting
OPTIMIZE-1 primary analysis: Safety, efficacy and biomarker results of a phase 1b/2 study combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).
First Author: Jean-Luc Van Laethem